Q4
WEB SYSTEMS

Sengenics Spotlights Research From NYU on Predicting Immune-Related Adverse Events (irAEs) at ASCO Annual Meeting

6/1/2023

BOSTON--(BUSINESS WIRE)-- Sengenics Corporation LLC, driving the discovery of next-gen biomarkers through its immunoproteomics platform, is pleased to announce that Dr. Iman Osman, Director of the Interdisciplinary Melanoma Program at New York University Grossman School of Medicine, will be presenting groundbreaking findings at the American Association of Clinical Oncologists (ASCO) Annual Meeting in Chicago, June 2nd – 6th, 2023. Her poster, titled "Determinants of racial disparities in immune-related adverse events (irAE) with checkpoint inhibition (ICI) in melanoma" (Abstract #9549, Poster Board # 312), sheds light on the prediction of irAEs in patients treated with checkpoint inhibitors. The predictive antibody data were generated with the Sengenics immunoprofiling platform.

The emergence of immune checkpoint inhibitors has revolutionized cancer treatment by effectively countering cancer cells' suppression of the cytotoxic T-cell response. They have revolutionized the field and brought hope to many patients. However, these inhibitors often give rise to immune-related adverse events (irAEs). The ability to predict the occurrence of irAEs would significantly enhance clinicians' decision-making in treatment protocols.

Dr. Osman's research investigates the hypothesis that patients susceptible to irAEs may exhibit baseline antibody profiles that hold predictive value for their response. Notably, she is extending her investigation to identify predictive signatures within underrepresented minority populations.

"I believe it is of utmost importance to develop predictive models that can be universally applicable, encompassing

all patients and not solely the majority population," stated Dr. Osman. "Recognizing the diversity in immune responses and avoiding the oversimplification of assuming what works for one group will work for another is crucial."

Jerry Williamson, President, and CEO of Sengenics, expressed enthusiasm for promoting Dr. Osman's critical work, stating, "We are thrilled to support Dr. Osman's groundbreaking research, as it contributes to the growing body of evidence supporting the value of antibody biomarkers."

Dr. Osman currently serves as the Associate Dean for Clinical Research Strategy and Director of the Interdisciplinary Melanoma Program at New York University Grossman School of Medicine. Her primary focus revolves around conducting translational research in melanoma where she spearheads the Melanoma Research Enterprise at NYU.

About Sengenics

Sengenics is an immunoproteomics company working to improve patient outcomes through physiologically relevant, data-guided decision making. Our solutions empower the discovery and validation of autoantibody biomarker signatures, enabling patient stratification, endotyping and therapeutic response prediction. Headquartered in Greater Boston, Massachusetts, USA, Sengenics Corporation LLC operates globally with offices in multiple locations. To learn more, visit **www.sengenics.com**.

Investor Contact:
Jerry Williamson
President & CEO, Sengenics Corporation
j.williamson@sengenics.com

Media Contact:
Katy McGirr
Director of Global Marketing, Sengenics Corporation
k.mcgirr@sengenics.com

Source: Sengenics Corporation LLC